Golidocitinib Pilot Study in Mycosis Fungoides and T-LGLL Initiated
A pilot study of golidocitinib is enrolling patients with advanced-stage mycosis fungoides/Sézary syndrome and T-cell large granular lymphocytic leukemia.
Asset / Drug
Drug and asset intelligence for Golidocitinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.